Effect of expanded dulaglutide weekly doses (3.0 mg and 4.5 mg) on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysis of the AWARD‐11 study

AIMS: This post hoc analysis investigated the effect of dulaglutide on cardiovascular disease (CVD) risk factors in subgroups of participants at increased CVD risk in the AWARD‐11 study. METHODS: Participants who received once weekly dulaglutide 1.5, 3.0 or 4.5 mg for 52 weeks were categorized accor...

Descripción completa

Detalles Bibliográficos
Autores principales: Cox, David A., Wang, Hui, Nicolay, Claudia, Bethel, Mary Angelyn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543252/
https://www.ncbi.nlm.nih.gov/pubmed/35546790
http://dx.doi.org/10.1111/dom.14762

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543252/
https://www.ncbi.nlm.nih.gov/pubmed/35546790
http://dx.doi.org/10.1111/dom.14762

Ejemplares similares